131 related articles for article (PubMed ID: 35352655)
21. PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
Alderuccio JP; Reis IM; Hamadani M; Nachiappan M; Leslom S; Kahl BS; Ai WZ; Radford J; Solh M; Ardeshna KM; Hess BT; Lunning MA; Zinzani PL; Stathis A; Carlo-Stella C; Lossos IS; Caimi PF; Han S; Yang F; Kuker RA; Moskowitz CH
Clin Cancer Res; 2024 Jan; 30(1):139-149. PubMed ID: 37855688
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.
Xie M; Wu K; Liu Y; Jiang Q; Xie Y
Med Oncol; 2015 Jan; 32(1):446. PubMed ID: 25511321
[TBL] [Abstract][Full Text] [Related]
23. The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in
Driessen J; Zwezerijnen GJC; Schöder H; Drees EEE; Kersten MJ; Moskowitz AJ; Moskowitz CH; Eertink JJ; Vet HCW; Hoekstra OS; Zijlstra JM; Boellaard R
J Nucl Med; 2022 Sep; 63(9):1424-1430. PubMed ID: 34992152
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
25. Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium.
Barrington SF; Zwezerijnen BGJC; de Vet HCW; Heymans MW; Mikhaeel NG; Burggraaff CN; Eertink JJ; Pike LC; Hoekstra OS; Zijlstra JM; Boellaard R
J Nucl Med; 2021 Mar; 62(3):332-337. PubMed ID: 32680929
[TBL] [Abstract][Full Text] [Related]
26. PET-derived tumor metrics predict DLBCL response and progression-free survival.
Islam P; Goldstein J; Flowers CR
Leuk Lymphoma; 2019 Aug; 60(8):1965-1971. PubMed ID: 30714446
[TBL] [Abstract][Full Text] [Related]
27. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas.
Prieto Prieto JC; Vallejo Casas JA; Hatzimichael E; Fotopoulos A; Kiortsis DN; Sioka C
Ann Nucl Med; 2020 Oct; 34(10):707-717. PubMed ID: 32924071
[TBL] [Abstract][Full Text] [Related]
28. Tumour necrosis as assessed with
Kahle XU; Hovingh M; Noordzij W; Seitz A; Diepstra A; Visser L; van den Berg A; van Meerten T; Huls G; Boellaard R; Kwee TC; Nijland M
Eur Radiol; 2019 Nov; 29(11):6018-6028. PubMed ID: 31028445
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG PET/CT in the diagnosis of an extranodal relapse of diffuse large B-cell lymphoma (DLBCL): a clinical case with a literature review.
Chaushev B; Micheva I; Mechmed M; Balev B; Bocheva Y; Ivanova D; Krasnaliev I; Lozanova R; Klisarova A; Bochev P; Dancheva J
Nucl Med Rev Cent East Eur; 2016; 19(B):11-13. PubMed ID: 27813622
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic Value of
Su JM; Zheng QZ; Huang WR; Deng J; Wu J; Lu HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500
[TBL] [Abstract][Full Text] [Related]
31. The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.
Choi JH; Lim I; Byun BH; Kim BI; Choi CW; Kang HJ; Shin DY; Lim SM
PLoS One; 2022; 17(9):e0273839. PubMed ID: 36156599
[TBL] [Abstract][Full Text] [Related]
32. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma.
Man S; Yan J; Li J; Cao Y; Hu J; Ma W; Liu J; Zhao Q
Int J Med Sci; 2021; 18(8):1857-1865. PubMed ID: 33746603
[TBL] [Abstract][Full Text] [Related]
33. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.
Ilyas H; Mikhaeel NG; Dunn JT; Rahman F; Møller H; Smith D; Barrington SF
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1142-1154. PubMed ID: 29460024
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of retention index of bone marrow on dual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma.
Chang CC; Cho SF; Chuang YW; Lin CY; Huang YF; Tyan YC
Medicine (Baltimore); 2018 Jan; 97(2):e9513. PubMed ID: 29480842
[TBL] [Abstract][Full Text] [Related]
35. Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on
Senjo H; Kanaya M; Izumiyama K; Minauchi K; Hirata K; Mori A; Saito M; Tanaka M; Iijima H; Tsukamoto E; Itoh K; Ota S; Morioka M; Hashimoto D; Teshima T;
Cancer Med; 2019 Mar; 8(3):953-962. PubMed ID: 30790452
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
van Heek L; Stuka C; Kaul H; Müller H; Mettler J; Hitz F; Baues C; Fuchs M; Borchmann P; Engert A; Dietlein M; Voltin CA; Kobe C
BMC Cancer; 2022 Jun; 22(1):672. PubMed ID: 35717166
[TBL] [Abstract][Full Text] [Related]
37. Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden.
Barrington SF; Meignan M
J Nucl Med; 2019 Aug; 60(8):1096-1102. PubMed ID: 30954945
[TBL] [Abstract][Full Text] [Related]
38. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
[TBL] [Abstract][Full Text] [Related]
39. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
[TBL] [Abstract][Full Text] [Related]
40. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
Cottereau AS; Meignan M; Nioche C; Capobianco N; Clerc J; Chartier L; Vercellino L; Casasnovas O; Thieblemont C; Buvat I
Ann Oncol; 2021 Mar; 32(3):404-411. PubMed ID: 33278600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
